Vanguard Global Advisers
YARW

Vanguard Global Advisers’s Yarrow Bioscience YARW Stock Holding History

Vanguard Global Advisers’s Portfolio YARW Stock Details YARW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-20
Closed -$600 – 3742
2026
Q1 		$600 Buy
+20
New +$583 ﹤0.01% 3656

Other funds holding YARW

ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SC
Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return
TC
T3 Companies New York $93.7M AUM
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
KCA
KVP Capital Advisors San Francisco, California $136M AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Global Advisers's YARW Position: Q2 2026 in Review

Vanguard Global Advisers sold out of Yarrow Bioscience (YARW) in Q2 2026, closing a stake of 20 shares — an estimated $600 sold.

Vanguard Global Advisers first reported a position in YARW in Q1 2026 and held it in 1 quarter. The position peaked at $600 in Q1 2026. 40 funds tracked by Wall St. Rank hold YARW as of Q2 2026.

  • Vanguard Global Advisers reported no remaining Yarrow Bioscience position as of Q2 2026 after selling out during the quarter.
  • Vanguard Global Advisers sold 20 Yarrow Bioscience shares in Q2 2026, an estimated $600.
  • Vanguard Global Advisers first reported a position in Yarrow Bioscience in Q1 2026 and held it in 1 quarter.
  • Vanguard Global Advisers's Yarrow Bioscience position peaked at $600 in Q1 2026.
  • 40 funds tracked by Wall St. Rank held Yarrow Bioscience as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.